Clinical Trial

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Study acronym: CLEAR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.
Protocol Amendment History 4 changes
critical Recruitment opened 2026-07-31
notable Trial sites expanded: 1 -> 34 locations 2026-07-31
notable Primary completion pushed: 2030-01-15 -> 2030-04-30 2026-07-31
minor Completion pushed: 2030-01-15 -> 2030-04-30 2026-07-31
Trial Details
NCT Number NCT07197307
Lead Sponsor Universität Münster
Collaborators: AbbVie, Sobi, Inc.
Conditions Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Enrollment 120 participants
Start Date 2025-10-31
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-30